表紙
市場調查報告書

北美的自我血糖監測(SMBG)市場 - 成長,趨勢,預測(2019年∼2024年)

North America Self-monitoring Blood Glucose Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 808284
出版日期 內容資訊 英文 80 Pages
商品交期: 2-3個工作天內
價格
北美的自我血糖監測(SMBG)市場 - 成長,趨勢,預測(2019年∼2024年) North America Self-monitoring Blood Glucose Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年08月01日內容資訊: 英文 80 Pages
簡介

北美的自我血糖監測(SMBG)市場預測從2019年到2024年間,將以13.44%的年複合成長率成長。

本報告提供北美的自我血糖監測(SMBG)市場調查,市場概要,各零組件、各終端用戶的市場規模的變化與預測,市場成長要素及阻礙因素,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 自我血糖監測(SMBG)市場
    • 各零件(成果值、預測值)
      • 血糖儀
      • 測試紙
      • 採血針
    • 各終端用戶(成果值、預測值)
      • 醫院
      • 個人
  • 各地區
    • 北美

第6章 市場指標

  • 第一型糖尿病人口(實在數值、估計值)
  • 第二型糖尿病人口(實在數值、估計值)

第7章 競爭情形

  • 企業簡介
    • Abbott Diabetes Care
    • Roche
    • Johnson & Johnson
    • Dexcom
    • Medtronic
    • Arkray
    • Ascensia Diabetes Care
    • Agamatrix Inc.
    • Bionime Corporation
    • Acon
    • Medisana
    • Trivida
    • Rossmax
  • 企業佔有率分析
    • Roche
    • Johnson&Johnson
    • Abbott Diabetes Care
    • 其他

第8章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 65472

The North America self-monitoring blood glucose (SMBG) market is expected to witness a CAGR of above 8% during the forecast period (2020-2025). As per the ADA, around 67.3% of the cost for diabetes care in the US, is provided by government insurance (including Medicare, Medicaid, and the military). The rest is paid for by private insurance (30.7%) or by the uninsured (2%).​ Since 1998, the US government has invested USD 2.5 billion towards Type 1 diabetic research through the Special Diabetes Program. Currently, the US government spends USD 150 million annually on diabetes research at the National Institutes of Health (NIH).​ Similarly, medical treatment standards in Canada are defined by the Canada Health Act of 1985 which empowers the Canadian government to regulate the safety and efficacy of medical devices, pharmaceuticals, and natural health products; fund health research; and administer a range of services for certain populations. ​ For the cost categories analyzed, care for people with diagnosed diabetes adds up to USD 1 in every USD 4 spent for healthcare in the United States, and more than 50% of that expenditure is directly accountable to diabetes.

Key Market Trends

Blood Glucose Test Strips Held the Largest Market Share in 2019

In 2019, Blood glucose test strips accounted for about 81% of the North America SMBG market. The glucometer is considered to be a one-time purchase. However, test strips, on the other hand, are a continuous investment, as a test strip needs to be disposed of after one use. Thus, it presents a considerable cost impact to the consumers. In North America demand for blood glucose test strips is projected to witness significant growth over the forecast period. The growth of the market studied is expected to be spurred by the rising diabetic population in the North American region. The growth in market volumes and share of the test strip segment is expected to be better than that of glucometers, because of the difference in the use-case frequency. While an average glucose meter lasts anywhere between six months and three years, presenting a one-time cost, during the same time frame, the corresponding use of multiple (in the range of thousands) test strips may occur, causing a recurrent cost impact.

The United States Held the Largest Market Share in 2019

The diabetic population in the United States is expected to cross 40 million by 2045, and in 2019 United States registered about 10 million obese population. Monitoring blood glucose levels is necessary, as poor blood glucose levels result in diabetes-related complications, like diabetic retinopathy, diabetic neuropathy, etc. In the United States, the type 1 diabetes population is expected to witness a CAGR of 1.01% for the coming years. In North America Blood glucose meters are now portable and accurate to use. Advancements in technology in SMBG devices have bought awareness among patients in the use of the products at home. The SMBG market in the United States is estimated to value greater than USD 4 billion in 2019.

Competitive Landscape

The North America self-monitoring blood glucose market is fragmented, with a few major manufacturers having a global market presence, while the remaining manufacturers confined to local or region-specific manufacturers. Mergers and acquisitions that occurred between the players in the recent past have helped companies strengthen their market presence. Panasonic acquired Bayer's diabetes care unit and named it Ascensia diabetes care, which continued its operations in North America.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Self-monitoring Blood Glucose Devices
    • 5.1.1 By Component (Value and Volume, 2012-2025)
      • 5.1.1.1 Glucometer Devices
      • 5.1.1.2 Test Strips
      • 5.1.1.3 Lancets
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value and Volume, 2012-2025)
      • 5.2.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.2.1.2 Canada (Value and Volume, 2012-2025)
      • 5.2.1.2.1 By Component (Glucometer Device, Test strips, Lancets)
      • 5.2.1.3 Rest of North America (Value and Volume, 2012-2025)
      • 5.2.1.3.1 By Component (Glucometer Device, Test strips, Lancets)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2012-2025)
  • 6.2 Type-2 Diabetes Population (2012-2025)

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Abbott
    • 7.1.2 F. Hoffmann-La Roche AG
    • 7.1.3 Platinum Equity (LifeScan)
    • 7.1.4 Arkray
    • 7.1.5 Ascensia
    • 7.1.6 Agamatrix Inc.
    • 7.1.7 Bionime Corporation
    • 7.1.8 Acon
    • 7.1.9 Medisana
    • 7.1.10 Trivida
    • 7.1.11 Rossmax

8 MARKET OPPORTUNITIES AND FUTURE TRENDS